2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 320

Sustained Improvement In Health-Related Quality Of Life, Work Productivity, Employability, and Reduced Healthcare Resource Utilization Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Golimumab: 5-Year Results From 3 Phase III Studies
Abstract Number: 2530

Sustained Improvements In Health-Related Quality Of Life In Patients With Systemic Lupus Erythematosus following Epratuzumab Treament: Results from a Phase IIb Trial and Its Open-Label Extension
Abstract Number: 1603

Sustained Reductions In Circulating B Cell Populations and Immunoglobulin G Levels With Long-Term Belimumab Treatment In Patients With Systemic Lupus Erythematosus
Abstract Number: 2265

Switching From Immediate Release (IR) Prednisone To Delayed Release (DR) Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional Disease-Modifying Antirheumatic Drugs (DMARDs)
Abstract Number: 579

Switching Treatment Between Mycophenolate Mofetil and Azathioprine In Lupus Patients The Reasons and The Effect
Abstract Number: 2257

Symptom Complexes At The Beginning Of Rheumatoid Arthritis: A Qualitative Exploration In At Risk Individuals and In New Patients Prior To Diagnosis
Abstract Number: 2434

Syndesmophyte Distribution Along The Vertebral Rim In Ankylosing Spondylitis Is Non-Random
Abstract Number: 943

Synergism Between Granulocyte-Macrophage Colony Stimulating Factor and Interleukin-17 Causes Joint Damage Via The Production Of Interleukin-23, Receptor Activator Of NF-κB Ligand and S100A8
Abstract Number: 2151

Synergistic Effect of Combining BioniCare® in an Unloading Brace for Osteoarthritis of the Knee
Abstract Number: 2565

Synergistic Effects Of Endothelin-1 On Transforming Growth Factor-β1 (TGF-β1) Induced Endothelial-To-Mesenchymal Transition. A Novel Mechanism For The Fibrogenic Effects Of Endothelin
Abstract Number: 1089

Synergistic Effects Of Transcranial Direct Current Stimulation and Trigger Point Injection For Treatment Of Myofascial Pain Syndrome: A Pilot Study With Randomized, Single-Blinded Trial
Abstract Number: 1375

Synergistic Enhancement Of Aggregated IgG-Induced Tumor Necrosis Factor α In Human Synovial Mast Cells By Interleukin 33
Abstract Number: 79

Synovial Activation In Experimental OA Drives Immuno suppressive Effects Of Adipose-derived Stem Cells After Local Administration and Protects Against Chondrogenesis In Ligaments
Abstract Number: 1314

Synovial Ectopic Lymphoneogenesis Predicts Clinical Response To Certolizumab Pegol In Patients With Rheumatoid Arthritis
Abstract Number: 2805

Synovial Explant Inflammatory Mediator Production Is Associated With Synovitis While Not With Bone Marrow Edema In Rheumatoid Arthritis: A Cross Sectional Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].